vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and STAG Industrial, Inc. (STAG). Click either name above to swap in a different company.
STAG Industrial, Inc. is the larger business by last-quarter revenue ($224.2M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 8.7%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Stag Arms is a firearms manufacturer founded in May 2003 and located in Cheyenne, Wyoming. Stag Arms is a manufacturer of the AR-15 type rifle, marketed as Stag-15 rifles. Stag advertises that all their weapons and accessories are made in the United States. They are best known for their left-handed AR-15 rifles, which use a mirror imaged upper receiver and have the ejection port reversed for left-handed shooters and the safety selector control on the right side of the lower receiver.
ESPR vs STAG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $224.2M |
| Net Profit | — | $62.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 27.6% |
| Revenue YoY | 143.7% | 9.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $224.2M | ||
| Q4 25 | $168.4M | $220.9M | ||
| Q3 25 | $87.3M | $211.1M | ||
| Q2 25 | $82.4M | $207.6M | ||
| Q1 25 | $65.0M | $205.6M | ||
| Q4 24 | $69.1M | $199.3M | ||
| Q3 24 | $51.6M | $190.7M | ||
| Q2 24 | $73.8M | $189.8M |
| Q1 26 | — | $62.0M | ||
| Q4 25 | — | $83.5M | ||
| Q3 25 | $-31.3M | $48.6M | ||
| Q2 25 | $-12.7M | $50.0M | ||
| Q1 25 | $-40.5M | $91.4M | ||
| Q4 24 | — | $51.0M | ||
| Q3 24 | $-29.5M | $41.9M | ||
| Q2 24 | $-61.9M | $59.8M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — |
| Q1 26 | — | 27.6% | ||
| Q4 25 | — | 37.8% | ||
| Q3 25 | -35.9% | 23.0% | ||
| Q2 25 | -15.4% | 24.1% | ||
| Q1 25 | -62.2% | 44.5% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | -57.2% | 21.9% | ||
| Q2 24 | -83.9% | 31.5% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $8.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $3.6B |
| Total Assets | $465.9M | $7.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $8.9M | ||
| Q4 25 | $167.9M | $14.9M | ||
| Q3 25 | $92.4M | $17.3M | ||
| Q2 25 | $86.1M | $15.4M | ||
| Q1 25 | $114.6M | $9.3M | ||
| Q4 24 | $144.8M | $36.3M | ||
| Q3 24 | $144.7M | $70.0M | ||
| Q2 24 | $189.3M | $33.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.8B |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $-302.0M | $3.6B | ||
| Q3 25 | $-451.4M | $3.4B | ||
| Q2 25 | $-433.5M | $3.4B | ||
| Q1 25 | $-426.2M | $3.5B | ||
| Q4 24 | $-388.7M | $3.5B | ||
| Q3 24 | $-370.2M | $3.3B | ||
| Q2 24 | $-344.2M | $3.3B |
| Q1 26 | — | $7.2B | ||
| Q4 25 | $465.9M | $7.2B | ||
| Q3 25 | $364.0M | $6.9B | ||
| Q2 25 | $347.1M | $6.8B | ||
| Q1 25 | $324.0M | $6.8B | ||
| Q4 24 | $343.8M | $6.8B | ||
| Q3 24 | $314.1M | $6.6B | ||
| Q2 24 | $352.3M | $6.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.91× | ||
| Q3 25 | — | 0.91× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.84× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 3.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $104.5M | ||
| Q3 25 | $-4.3M | $143.5M | ||
| Q2 25 | $-31.4M | $111.9M | ||
| Q1 25 | $-22.6M | $103.5M | ||
| Q4 24 | $-35.0M | $104.9M | ||
| Q3 24 | $-35.3M | $128.0M | ||
| Q2 24 | $-7.2M | $122.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.8M | ||
| Q3 25 | — | $95.5M | ||
| Q2 25 | — | $62.3M | ||
| Q1 25 | — | $57.2M | ||
| Q4 24 | — | $37.6M | ||
| Q3 24 | $-35.5M | $86.7M | ||
| Q2 24 | $-7.3M | $105.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.8% | ||
| Q3 25 | — | 45.2% | ||
| Q2 25 | — | 30.0% | ||
| Q1 25 | — | 27.8% | ||
| Q4 24 | — | 18.8% | ||
| Q3 24 | -68.7% | 45.5% | ||
| Q2 24 | -9.9% | 55.3% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 0.0% | 27.4% | ||
| Q3 25 | 0.0% | 22.7% | ||
| Q2 25 | 0.0% | 23.9% | ||
| Q1 25 | 0.0% | 22.5% | ||
| Q4 24 | 0.0% | 33.8% | ||
| Q3 24 | 0.3% | 21.6% | ||
| Q2 24 | 0.1% | 9.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.25× | ||
| Q3 25 | — | 2.95× | ||
| Q2 25 | — | 2.24× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 2.06× | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | 2.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
STAG
Segment breakdown not available.
